Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats

Yang Gao, Elena Atanasova, Nan Sui, James D. Pancook, Jeffry D. Watkins, William Stephen Brimijoin

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We previously found that injection of a cocaine hydrolase (CocE) engineered from human butyrylcholinesterase will transiently accelerate cocaine metabolism in rats while reducing physiological and behavioral responses. To investigate more extended therapeutic effects, CocE cDNA was incorporated into a replication-incompetent type-5 adenoviral vector with a cytomegalovirus promoter. In rats dosed with this agent (2.2 × 109 plaque-forming units), the time course of expression was characterized by reverse transcription polymerase chain reaction for CocE mRNA and by radiometric assay for enzyme activity. Liver and plasma showed comparable expression, beginning 2 days after vector administration and peaking between 5 and 7 days. Plasma CocE content was up to 100 mU/ml, with total cocaine hydrolyzing activity 3000-fold greater than in "empty vector" or untreated controls. This level of expression approximated that found immediately after i.v. injection of purified hydrolase, 3 mg/kg, a dose that shortened cocaine half-life and blunted cardiovascular effects. Sucrose density gradient analysis showed that 96% of the circulating CocE activity was associated with tetrameric enzyme forms, expected to be stable in vivo. Consistent with this expectation, CocE from vector-treated rats showed a plasma t1/2 of 33 h when reinjected into naive rats. Transduction of another mutant butyrylcholinesterase, Applied Molecular Evolution mutant 359 (AME359), caused plasma cocaine hydrolase activity to rise 50,000-fold. At the point of peak AME359 expression, cocaine was cleared from the blood too rapidly for accurate measurement, and pressor responses to the injection of drug were greatly impaired.

Original languageEnglish (US)
Pages (from-to)204-211
Number of pages8
JournalMolecular Pharmacology
Volume67
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Hydrolases
Cocaine
Genes
Butyrylcholinesterase
Molecular Evolution
Injections
Enzyme Assays
Therapeutic Uses
Cytomegalovirus
Reverse Transcription
Half-Life
Sucrose
Complementary DNA
Polymerase Chain Reaction
Messenger RNA
Liver
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. / Gao, Yang; Atanasova, Elena; Sui, Nan; Pancook, James D.; Watkins, Jeffry D.; Brimijoin, William Stephen.

In: Molecular Pharmacology, Vol. 67, No. 1, 01.2005, p. 204-211.

Research output: Contribution to journalArticle

Gao, Yang ; Atanasova, Elena ; Sui, Nan ; Pancook, James D. ; Watkins, Jeffry D. ; Brimijoin, William Stephen. / Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. In: Molecular Pharmacology. 2005 ; Vol. 67, No. 1. pp. 204-211.
@article{389b33dbdc0f431180b5e7a01ff21796,
title = "Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats",
abstract = "We previously found that injection of a cocaine hydrolase (CocE) engineered from human butyrylcholinesterase will transiently accelerate cocaine metabolism in rats while reducing physiological and behavioral responses. To investigate more extended therapeutic effects, CocE cDNA was incorporated into a replication-incompetent type-5 adenoviral vector with a cytomegalovirus promoter. In rats dosed with this agent (2.2 × 109 plaque-forming units), the time course of expression was characterized by reverse transcription polymerase chain reaction for CocE mRNA and by radiometric assay for enzyme activity. Liver and plasma showed comparable expression, beginning 2 days after vector administration and peaking between 5 and 7 days. Plasma CocE content was up to 100 mU/ml, with total cocaine hydrolyzing activity 3000-fold greater than in {"}empty vector{"} or untreated controls. This level of expression approximated that found immediately after i.v. injection of purified hydrolase, 3 mg/kg, a dose that shortened cocaine half-life and blunted cardiovascular effects. Sucrose density gradient analysis showed that 96{\%} of the circulating CocE activity was associated with tetrameric enzyme forms, expected to be stable in vivo. Consistent with this expectation, CocE from vector-treated rats showed a plasma t1/2 of 33 h when reinjected into naive rats. Transduction of another mutant butyrylcholinesterase, Applied Molecular Evolution mutant 359 (AME359), caused plasma cocaine hydrolase activity to rise 50,000-fold. At the point of peak AME359 expression, cocaine was cleared from the blood too rapidly for accurate measurement, and pressor responses to the injection of drug were greatly impaired.",
author = "Yang Gao and Elena Atanasova and Nan Sui and Pancook, {James D.} and Watkins, {Jeffry D.} and Brimijoin, {William Stephen}",
year = "2005",
month = "1",
doi = "10.1124/mol.104.006924",
language = "English (US)",
volume = "67",
pages = "204--211",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats

AU - Gao, Yang

AU - Atanasova, Elena

AU - Sui, Nan

AU - Pancook, James D.

AU - Watkins, Jeffry D.

AU - Brimijoin, William Stephen

PY - 2005/1

Y1 - 2005/1

N2 - We previously found that injection of a cocaine hydrolase (CocE) engineered from human butyrylcholinesterase will transiently accelerate cocaine metabolism in rats while reducing physiological and behavioral responses. To investigate more extended therapeutic effects, CocE cDNA was incorporated into a replication-incompetent type-5 adenoviral vector with a cytomegalovirus promoter. In rats dosed with this agent (2.2 × 109 plaque-forming units), the time course of expression was characterized by reverse transcription polymerase chain reaction for CocE mRNA and by radiometric assay for enzyme activity. Liver and plasma showed comparable expression, beginning 2 days after vector administration and peaking between 5 and 7 days. Plasma CocE content was up to 100 mU/ml, with total cocaine hydrolyzing activity 3000-fold greater than in "empty vector" or untreated controls. This level of expression approximated that found immediately after i.v. injection of purified hydrolase, 3 mg/kg, a dose that shortened cocaine half-life and blunted cardiovascular effects. Sucrose density gradient analysis showed that 96% of the circulating CocE activity was associated with tetrameric enzyme forms, expected to be stable in vivo. Consistent with this expectation, CocE from vector-treated rats showed a plasma t1/2 of 33 h when reinjected into naive rats. Transduction of another mutant butyrylcholinesterase, Applied Molecular Evolution mutant 359 (AME359), caused plasma cocaine hydrolase activity to rise 50,000-fold. At the point of peak AME359 expression, cocaine was cleared from the blood too rapidly for accurate measurement, and pressor responses to the injection of drug were greatly impaired.

AB - We previously found that injection of a cocaine hydrolase (CocE) engineered from human butyrylcholinesterase will transiently accelerate cocaine metabolism in rats while reducing physiological and behavioral responses. To investigate more extended therapeutic effects, CocE cDNA was incorporated into a replication-incompetent type-5 adenoviral vector with a cytomegalovirus promoter. In rats dosed with this agent (2.2 × 109 plaque-forming units), the time course of expression was characterized by reverse transcription polymerase chain reaction for CocE mRNA and by radiometric assay for enzyme activity. Liver and plasma showed comparable expression, beginning 2 days after vector administration and peaking between 5 and 7 days. Plasma CocE content was up to 100 mU/ml, with total cocaine hydrolyzing activity 3000-fold greater than in "empty vector" or untreated controls. This level of expression approximated that found immediately after i.v. injection of purified hydrolase, 3 mg/kg, a dose that shortened cocaine half-life and blunted cardiovascular effects. Sucrose density gradient analysis showed that 96% of the circulating CocE activity was associated with tetrameric enzyme forms, expected to be stable in vivo. Consistent with this expectation, CocE from vector-treated rats showed a plasma t1/2 of 33 h when reinjected into naive rats. Transduction of another mutant butyrylcholinesterase, Applied Molecular Evolution mutant 359 (AME359), caused plasma cocaine hydrolase activity to rise 50,000-fold. At the point of peak AME359 expression, cocaine was cleared from the blood too rapidly for accurate measurement, and pressor responses to the injection of drug were greatly impaired.

UR - http://www.scopus.com/inward/record.url?scp=11244266133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244266133&partnerID=8YFLogxK

U2 - 10.1124/mol.104.006924

DO - 10.1124/mol.104.006924

M3 - Article

VL - 67

SP - 204

EP - 211

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -